<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04007809</url>
  </required_header>
  <id_info>
    <org_study_id>DIATAG</org_study_id>
    <nct_id>NCT04007809</nct_id>
  </id_info>
  <brief_title>Phenotypic and Genotypic Characterization of New-onset Type I Diabetes</brief_title>
  <acronym>DIATAG</acronym>
  <official_title>Phenotypic and Genotypic Characterization of a Cohort of Pediatric Patients With New-onset Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fonds National de la Recherche Scientifique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BESPEED</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of DIATAG study is the identification of biomarkers of T1D evolution in a pediatric&#xD;
      cohort.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 diabetes (T1D) is a common chronic disease in childhood. Clinical presentation at&#xD;
      onset of T1D can vary among patients from long-standing diabetes triad symptoms (polyuria,&#xD;
      polydipsia and weight loss) to coma and ketoacidosis. The initial clinical presentation of&#xD;
      T1D was shown to have long-term influence on glycemic control of the patient. The&#xD;
      investigators initiated a collaborative consortium including six pediatric clinics in Belgium&#xD;
      to better characterize new-onset T1D patients.&#xD;
&#xD;
      Hypothesis :&#xD;
&#xD;
        1. Different subgroups of T1D patients might exist, underlying different physiopathology of&#xD;
           T1D :&#xD;
&#xD;
             -  The investigators will first investigate the presence of biomarkers in different&#xD;
                fluids (e.g. urine, blood, feces,...).&#xD;
&#xD;
             -  The investigators will correlate results with clinical parameters of glycemic&#xD;
                control. Dynamic tests (HOMA and stimulated C peptide) will be realized at 2&#xD;
                defined time points of the follow-up.&#xD;
&#xD;
        2. Glucose variability can be influenced by external factors (e.g. diet, physical activity,&#xD;
           Quality of Life (QoL),...) The investigators will evaluate those external factors using&#xD;
           approved questionnaires. They will presented to the patient and its parents at 2 defined&#xD;
           time points.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of T1D subgroups by using follow-up of clinical parameters : weight in kilograms</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>weight in kilograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of T1D subgroups by using follow-up of clinical parameters : Height in centimeter</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>Height in centimeter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of T1D subgroups by using follow-up of clinical parameters : Body mass index (kg/m²)</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>Body mass index (kg/m²)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of T1D subgroups by using follow-up of clinical parameters : glycemic variability (%)</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>glycemic variability (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-up of laboratory results - glycemia (mg/dL)</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>glycemia (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-up of laboratory results - Insulin (mUI/L)</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>Insulin (mUI/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-up of laboratory results - HbA1C (%)</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>HbA1C (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-up of laboratory results - C-peptide (mUI/L)</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>C-peptide (mUI/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation and follow-up of diet, physical activity, quality of life using validated questionnaires.</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>Composite of Physical Activity Questionnaire (PAQ), DisabKids, Health Behaviour in School-aged Children (HBSC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation and follow-up of physical activity</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>Physical Activity Questionnaire (PAQ). This questionnaire consists of 8 items. Once you have a value from 1 to 5 for each of the 8 items (items 1 to 8) used in the Physical Activity composite score, you simply take the mean of these 8 items, which results in the final PAQ activity summary score.&#xD;
A score of 1 indicates low physical activity, wheareas a score of 5 indicates high physical activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation and follow-up of quality of life: DisabKids Questionnaires</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>DisabKids Questionnaires. The paper version of DISABKIDS consisted of the generic health related quality of life questionnaire for 8- to 18-year-olds (37 items) and the DISABKIDS Diabetes module (10 items). The questionnaire is designed to measure health related quality of life of children with a chronic medical condition. Questions are answered on a Likert type scale of 1-5 points. Lower scores correspond to better quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Production of prediction model of β-cell mass evolution</measure>
    <time_frame>up to 18 months after diagnosis</time_frame>
    <description>Composite score using clinical parameters and laboratory results</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>New-onset Type 1 diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>Every patients will undergo stimulated C peptide test. Glucagon will be administered using intravenous route (0,03 mg/kg, max 1mg).</description>
    <arm_group_label>New-onset Type 1 diabetes</arm_group_label>
    <other_name>Glucagen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 1 diabetes de novo according to American Diabetes Association criteria:&#xD;
&#xD;
               1. Polyuria, polydipsia, weight loss ± ketoacidosis&#xD;
&#xD;
               2. Fasting blood glucose ≥126 mg/dL AND/OR blood glucose ≥200 mg/dL at the 120th&#xD;
                  minute of an Oral Glucose Tolerance Test (OGTT) AND/OR HbA1c ≥6.5% AND/OR a&#xD;
                  patient with symptoms of hyperglycemia/hyperglycemic crisis (see 8. a. 2.) with&#xD;
                  random blood glucose ≥200 mg/dL.&#xD;
&#xD;
               3. Presence in the serum of one or more anti-islet autoantibodies (anti-insulin,&#xD;
                  anti-IA2, anti-GAD65, anti-ZnT8)&#xD;
&#xD;
          2. Age between 6 months and 18 years.&#xD;
&#xD;
          3. Male or female.&#xD;
&#xD;
          4. Positive for one or more autoantibodies typically associated with Type 1 Diabetes&#xD;
             (TD1).&#xD;
&#xD;
          5. Free written and oral consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Children under 6 months of age.&#xD;
&#xD;
          2. Treatment that interferes with insulin secretion and insulin sensitivity (e. g.&#xD;
             sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids,&#xD;
             biguanide, incretins).&#xD;
&#xD;
          3. Presence of celiac disease (diagnosis based on pathological duodenal biopsy), recently&#xD;
             diagnosed (within 1 month), at the time of inclusion.&#xD;
&#xD;
          4. Autoimmune/auto-inflammatory disease (other than type 1 diabetes) or active malignant&#xD;
             disease present at inclusion.&#xD;
&#xD;
          5. Obesity defined by a Body Mass Index (BMI) with a z-score &gt;+3 Standard Deviation.&#xD;
&#xD;
          6. Hepatic, renal or adrenal insufficiency.&#xD;
&#xD;
          7. History of spinal cord allograft.&#xD;
&#xD;
          8. History of post-hemolytic-uremic diabetes.&#xD;
&#xD;
          9. Absence of anti-pancreatic islet auto-antibodies.&#xD;
&#xD;
         10. Dysmorphic with suspicion of underlying genetic syndrome.&#xD;
&#xD;
         11. Participation in another study within the previous 3 months, with administration of&#xD;
             blood derivatives or potentially immunomodulating treatments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe A Lysy, MD, PhD</last_name>
    <phone>0032 2 764 13 70</phone>
    <email>philippe.lysy@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier Polle, MD</last_name>
    <phone>0032 2 764 13 70</phone>
    <email>olivier.polle@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Lysy</last_name>
      <email>philippe.lysy@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Olivier Polle</last_name>
      <email>olivier.polle@uclouvain.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>children</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

